Dechert advised Antios Therapeutics on the deal.Antios Therapeutics, Inc. (“Antios”) completed its $96 million Series B financing. Antios is a clinical-stage biopharmaceutical company focused on the development…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now